Cited 196 times in
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.